Dissemination (Meeting Coverage)

First-line, fixed-duration ibrutinib plus venetoclax provides durable progression-free survival and overall survival for patients with CLL or SLL.

An online mindfulness-based stress reduction program reduced the symptomatic burden for patients with breast cancer, according to research from SABCS.

Using AI and remote patient monitoring technology in pain management enables ongoing real-time monitoring, facilitating personalized adjustments to therapy.

A new patient registry aims to integrate clinical and patient-reported data to improve care and guide personalized treatment in early breast cancer.

Luis Sumoza, MD, highlights the need to explain the disease, its consequences, and treatment side effects to patients, highlighting effective communication with primary care providers is crucial to ensure coordinated care.

Physician’s Weekly spoke with Richard Newcomb, MD, on the role of nurses and APs in enhancing palliative care.

Early palliative care improves transplant patients’ quality of life, especially for minoritized groups or those with high distress, suggesting targeted or clinician-led care.

iMMagine-1 phase 2 trial shows 97% response, 62% complete response in relapsed/refractory myeloma, with strong safety and promising 2026 launch.

NGS aligned with FISH for detecting HER2 status in patients with breast cancer, in addition to revealing ERBB2 mutations and nuanced alterations.

Physician’s Weekly spoke with Alexey Danilov, MD, PhD, at ASH 2024 on personalized care and prognostic insights in CLL.

Recent studies, including one from the ASHP Midyear Clinical Meeting, highlight strategies for achieving equitable outcomes in patients with chronic pain.

High tumor-infiltrating lymphocyte levels (>40%) predicted improved survival in triple-negative breast cancer, emphasizing TILs as a key prognostic biomarker.

A recent study evaluated the impact of circulating plasma cells in patients with primary multiple myeloma on bortezomib-containing induction therapy.

A recent study from ASH 2024 examined the clinical features and outcomes of RT in British Columbia, comparing two eras: the chemoimmunotherapy (CIT) era (pre-2016) and the novel agents (NA) era (post-2016).

Educational programs and psychological support addressing cancer-related beliefs and promoting healthier coping strategies are crucial for improving outcomes.

Molecular residual disease was detected about six months before radiographic confirmation of recurrence in patients with inflammatory breast cancer.

New research on breast cancer was presented at the San Antonio Breast Cancer Symposium 2024, including updates on HER2-enriched disease and lymphedema.

Will you be attending “Mind the Gap — Breast Cancer in the Young” at SABCS?

Treatment resistance and toxicity remain critical challenges in managing chronic lymphocytic leukemia (CLL), according to researchers at the ASH Annual Meeting.

Oral oncolytic therapies have revolutionized the treatment of chronic lymphocytic leukemia (CLL), offering improved outcomes and convenience for patients.